This trial is investigating a medication for treating people living with non-segmental vitiligo.
Vitiligo causes white patches on your skin when the cells that provide colour to your skin are destroyed. Non-segmental Vitiligo affects both sides of the body, such as both knees and both hands.
The investigational drug for this study is Ritlecitinib and is given as an oral tablet. Ritlecitinib is a treatment for diseases of a similar nature to vitiligo, and has been well tolerated in previous clinical trials.
The purpose of this research project is to measure how safe and effective this medication is in treating participants with non-segmental vitiligo. Ritlecitinib selectively inhibits the body’s immune response. The outcome of this project could support new treatments to increase quality of life in people with non-segmental vitiligo.
Ethics
All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by the Royal Melbourne Hospital HREC.
This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2007). This statement protects the interests of people who agree to participate in human research studies.